Intercept's NASH dreams may be dashed after FDA panel votes against Ocaliva's approval bid
Downvote
It looks like Intercept Pharmaceuticals’ Ocaliva still has a tough road ahead in nonalcoholic steatohepatitis (NASH) after a panel of FDA advisers voiced concerns with the company's application pac | It looks like Intercept Pharmaceuticals’ Ocaliva has a tough road ahead in nonalcoholic steatohepatitis after a panel of FDA advisers voiced concerns with the company's…
This story from fiercepharma.com was posted on 2023-05-20 by @glowbug.